Thymogen

Thymogen is a synthetic dipeptide with the sequence L-glutamyl-L-tryptophan (Glu-Trp, EW). The molecule was originally isolated by reverse-phase HPLC from Thymalin, a calf thymic peptide complex, and the synthetic dipeptide prepared on that basis was subsequently given the name Thymogen; the same compound carries the International Nonproprietary Name oglufanide and was investigated under the code IM-862. At 333.34 g/mol it is among the smallest peptides used as an immunological research tool, pairing the negatively charged side chain of glutamate with the aromatic indole ring of tryptophan. Because both enantiomeric forms of this dipeptide exist, note that this product is the L-L compound (L-Glu-L-Trp) and not the D-D isomer known as Thymodepressin, which is reported in the literature to act in the opposite direction. Thymogen has been studied in preclinical research on thymic and immune bioregulation, T-lymphocyte differentiation, natural killer cell function, and immunosenescence. This material is supplied for research use only and is not for human consumption.

In published preclinical models, Thymogen has been described as an immunostimulatory bioregulator rather than a directly cytotoxic compound. Reported effects include activation of T-cell differentiation and of T-cell recognition of peptide-MHC complexes, shifts in the intracellular balance of cyclic nucleotides, and stimulation of neutrophil chemotaxis and phagocytosis. In murine tumor models the dipeptide showed no direct toxicity against a panel of human tumor cell lines, and its in-vivo activity instead required intact cytolytic effector function: activity was lost in perforin-deficient animals and in animals carrying the Lyst mutation that disrupts cytoplasmic granule trafficking, was retained in IFN-gamma knockout animals, and was substantially diminished in IL-12 knockout animals, indicating an NK/NKT-cell-mediated and partly IL-12-dependent route. Chirality appears central to the direction of action, with the L-L form studied as an immunostimulant and the D-D enantiomer studied as an immunosuppressor, a reciprocal pairing that is itself an active subject of laboratory investigation.

Thymic Origin, Immunomodulatory Profile, and Aging Models

Anisimov, Khavinson, and Morozov (2000) reported that L-Glu-L-Trp was isolated from the natural calf thymic peptide complex Thymalin by reverse-phase HPLC, and that the synthetic dipeptide activated T-cell differentiation, T-cell recognition of peptide-MHC complexes, and neutrophil chemotaxis and phagocytosis. In a long-term study in female rats, treatment lowered the Gompertz aging-rate coefficient and reduced total, malignant, and hematopoietic tumor incidence relative to saline-treated controls [1].

NK-Cell Dependence of Antitumor Activity

Smith et al. (2003) reported that L-glutamyl-L-tryptophan inhibited tumor growth in mice without direct cytotoxicity against a panel of human tumor cell lines, and that this in-vivo activity required natural killer cell function. Activity was abolished in perforin-deficient animals and in animals carrying the Lyst granule-trafficking mutation, preserved in IFN-gamma knockouts, and significantly diminished in IL-12 knockouts [2].

Enantiomeric Pairing and Peptide Chirality

Deigin et al. (2024) reviewed Thymogen (L-Glu-L-Trp) alongside its D-enantiomer Thymodepressin as an example of reciprocal, up-and-down regulation of homeostasis by a chiral peptide pair, discussing peptide susceptibility to proteolysis and the enantiomeric selectivity of biological systems as a design axis for peptide research [3].